UNSPSC 85501229: Supplement left internal carotid artery with autologous tissue substitute, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement left internal carotid artery with autologous tissue substitute, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 03UL37Z

UNSPSC 85501229, Supplement left internal carotid artery with autologous tissue substitute, percutaneous approach, is a Commodity code whose nominal clinical descriptor does not align with the state and local procurement activity tagged under it. The recent opportunities posted against this code show no relevant medical device procurement, vascular surgery supplies, or tissue-substitution materials. Instead, the tagged solicitations are for occupational medical surveillance services (Washington State Department of Transportation), independent medical evaluation services for pension disability determinations (City of Phoenix), surgical benefit carve-out program administration (City of Long Beach), specialty medical services for detained youth (Harris County), pharmacy benefit management (Collier County), temporary health professional staffing (Santa Clara County Health System), and general RFI issuance for emergency and inpatient services (Harris County Juvenile Probation Department). None of these solicitations procure the cardiovascular implant or tissue substitute product that the code nominally describes.

The mismatch between code name and actual opportunity scope suggests either persistent miscoding or a classification error in the source data. The code shows no meaningful recent state and local procurement activity in its stated domain. Business development professionals should treat this code as inactive for the purposes of state and local government contracting and verify the correct UNSPSC classification for any actual cardiovascular implant or tissue-substitute business development.